Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer’s Risk – TheStreet.com

March 24, 2017 by  
Filed under Alzheimers News

Sponsored By

TheStreet.com
Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
TheStreet.com
Be wary of anyone offering rosy assessments of effective Alzheimer's drugs. Unicorns are easier to find. Lilly's sola failure last December was followed in February by the forced halt to Merck's (MRK) verubecestat phase III study due to futility at an

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

*